Effects of age on the glucose metabolic changes in mild cognitive impairment

American Journal of Neuroradiology

Volumn 31, Issue 7, 2010, Pages 1247-1253

  Kantarci, Kejal ^a   Senjem, M L ^a   Lowe, V J ^a   Wiste, H J ^a   Weigand, S D ^a   Kemp, B J ^a   Frank, A R ^b   Shiung, M M ^a   Boeve, B F ^a   Knopman, D S ^a   Petersen, R C ^a   Jack Jr , C R ^a  

^a MAYO CLINIC   (United States)

^b Élisabeth Bruyére Health Centre   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGE DISTRIBUTION; AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN ATROPHY; BRAIN REGION; CINGULATE GYRUS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOREBRAIN; FRONTAL LOBE; GLUCOSE METABOLISM; GRAY MATTER; HIPPOCAMPUS; HUMAN; LEFT HEMISPHERE; MALE; MILD COGNITIVE IMPAIRMENT; PARIETAL LOBE; POSITRON EMISSION TOMOGRAPHY; PRECUNEUS; RIGHT HEMISPHERE; TEMPORAL LOBE;

AGED; AGED, 80 AND OVER; AGING; ALZHEIMER DISEASE; ATROPHY; BIOLOGICAL MARKERS; BLOOD GLUCOSE; COGNITION DISORDERS; EARLY DIAGNOSIS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; PARIETAL LOBE; POSITRON-EMISSION TOMOGRAPHY; REPRODUCIBILITY OF RESULTS; TEMPORAL LOBE;

EID: 77955614659     PISSN: 01956108     EISSN: 1936959X     Source Type: Journal    
DOI: 10.3174/ajnr.A2070     Document Type: Article

References (34)

1. Thal LJ, Kantarci K, Reiman EM, et al. The role of biomarkers in clinical trials for Alzheimer disease. Alzheimer Dis Assoc Disord 2006;20:6-15 (Pubitemid 44356888)
2. Petersen RC, Stevens JC, Ganguli M, et al. Practice parameter: early detection of dementia - mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001;56:1133-42
3. Chetelat G, Desgranges B, de la Sayette V, et al. Mild cognitive impairment: can FDG-PET predict who is to rapidly convert to Alzheimer's disease? Neurology 2003;60:1374-77
4. De Santi S, de Leon MJ, Rusinek H, et al. Hippocampal formation glucose metabolism and volume losses in MCI and AD. Neurobiol Aging 2001;22:529-39 (Pubitemid 32607736)
5. Drzezga A, Lautenschlager N, Siebner H, et al. Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study. Eur J Nucl Med Mol Imaging 2003;30:1104-13 (Pubitemid 36988222)
6. Minoshima S, Giordani B, Berent S, et al. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann Neurol 1997;42:85-94
7. Nestor PJ, Fryer TD, Smielewski P, et al. Limbic hypometabolism in Alzheimer's disease and mild cognitive impairment. Ann Neurol 2003;54:343-51
8. Mosconi L, Brys M, Glodzik-Sobanska L, et al. Early detection of Alzheimer's disease using neuroimaging. Exp Gerontol 2007;42:129-38 (Pubitemid 44937821)
9. Kim EJ, Cho SS, Jeong Y, et al. Glucose metabolism in early onset versus late onset Alzheimer's disease: an SPM analysis of 120 patients. Brain 2005;128:1790-801
10. Sakamoto S, Ishii K, Sasaki M, et al. Differences in cerebral metabolic impairment between early and late onset types of Alzheimer's disease. J Neurol Sci 2002;200:27-32
11. Matsunari I, Samuraki M, Chen WP, et al. Comparison of 18F-FDG-PET and optimized voxel-based morphometry for detection of Alzheimer's disease: aging effect on diagnostic performance. J Nucl Med 2007;48:1961-70
12. Petersen RC, Kokmen E, Tangalos E, et al. Mayo Clinic Alzheimer's Disease Patient Registry. Aging (Milano) 1990;2:408-15
13. Kantarci K, Petersen RC, Przybelski SA, et al. Hippocampal volumes, proton magnetic resonance spectroscopy metabolites, and cerebrovascular disease in mild cognitive impairment subtypes. Arch Neurol 2008;65:1621-28
14. Murray ME, Shiung MM, Weigand SD, et al. Mayo MRI visual grading scale: validation studies. In: Proceedings of the 37th Annual Meeting of the Society for Neuroscience, San Diego, California. November 3-7, 2007
15. Tzourio-Mazoyer N, Landeau B, Papathanassiou D, et al. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage 2002;15:273-89 (Pubitemid 34852226)
16. Hoffman JM, Welsh-Bohmer KA, Hanson M, et al. FDG-PET imaging in patients with pathologically verified dementia. J Nucl Med 2000;41:1920-28
17. Jagust W, Reed B, Mungas D, et al. What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia? Neurology 2007;69:871-77 (Pubitemid 47329586)
18. Silverman DH, Small GW, Chang CY, et al. Positron emission tomography in evaluation of dementia: regional brain metabolism and long-term outcome. JAMA 2001;286:2120-27
19. Vemuri P, Whitwell JL, Kantarci K, et al. Antemortem MRI based STructural Abnormality iNDex (STAND)-scores correlate with postmortem Braak neurofibrillary tangle stage. Neuroimage 2008;42:559-67. Epub 2008 May 20
20. Ashburner J, Friston KJ. Unified segmentation. Neuroimage 2005;26:839-51
21. Meltzer CC, Kinahan PE, Greer PJ, et al. Comparative evaluation of MR-based partial-volume correction schemes for PET. J Nucl Med 1999;40:2053-65
22. Sun FT, Schriber RA, Greenia JM, et al. Automated template-based PET region of interest analyses in the aging brain. Neuroimage 2007;34:608-17
23. Vemuri P, Gunter JL, Senjem ML, et al. Alzheimer's disease diagnosis in individual subjects using structural MR images: validation studies. Neuroimage 2008;39:1186-97
24. Roberts RO, Geda YE, Knopman DS, et al. The Mayo Clinic Study of Aging: design and sampling, participation, baseline measures and sample characteristics. Neuroepidemiology 2008;30:58-69. Epub 2008 Feb 7
25. Anchisi D, Borroni B, Franceschi M, et al. Heterogeneity of brain glucose metabolism in mild cognitive impairment and clinical progression to Alzheimer disease. Arch Neurol 2005;62:1728-33
26. Bigio EH, Hynan LS, Sontag E, et al. Synapse loss is greater in presenile than senile onset Alzheimer disease: implications for the cognitive reserve hypothesis. Neuropathol Appl Neurobiol 2002;28:218-27
27. Bennett DA, Wilson RS, Schneider JA, et al. Natural history of mild cognitive impairment in older persons. Neurology 2002;59:198-205
28. Jicha GA, Parisi JE, Dickson DW, et al. Neuropathologic outcome of mild cognitive impairment following progression to clinical dementia. Arch Neurol 2006;63:674-81
29. Morris JC, Price AL. Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer's disease. J Mol Neurosci 2001;17:101-18
30. Petersen RC, Parisi JE, Dickson DW, et al. Neuropathologic features of amnestic mild cognitive impairment. Arch Neurol 2006;63:665-72
31. Storandt M, Grant EA, Miller JP, et al. Longitudinal course and neuropathologic outcomes in original vs revised MCI and in pre-MCI. Neurology 2006;67:467-73 (Pubitemid 44214972)
32. Schneider JA, Arvanitakis Z, Bang W, et al. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology 2007;69:2197-204
33. Seo SW, Cho SS, Park A, et al. Subcortical vascular versus amnestic mild cognitive impairment: comparison of cerebral glucose metabolism. J Neuroimaging 2009;19:213-9. Epub 2009 Nov 3
34. Savva GM, Wharton SB, Ince PG, et al. Age, neuropathology, and dementia. N Engl J Med 2009;360:2302-09